1. Introduction {#sec1}
===============

More people than ever die from cancer. After cardiovascular diseases, cancer is the second biggest health problem accounting for an estimated 9.56 million deaths worldwide in 2017. The number of cancer deaths increased between 1990 and 2017 by 66%. For example in the same year, 259,671 deaths worldwide accounted for cervical cancer and 247,143 deaths accounted for brain and nervous system cancers, respectively ([@bib51]). In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States ([@bib49]). Worldwide, one in five men and one in six women develop cancer during their lifetimes. The five-year-prevalence figure is estimated to be 43.8 million cases globally and is expected to rise by 22 million annually within the next two decades ([@bib4]). Treatment of cancer currently includes the surgical removal of cancerous tissue, radiotherapy, chemotherapy, and a combination of chemotherapy and target therapy. The use of anticancer drugs (chemotherapy), while often more beneficial when used in conjugation with radiation therapy or surgery, and are nonetheless a key line of treatment. Because cytotoxic drugs are the mainstay of chemotherapy, it is important to discover novel cytotoxic agents with diverse activity, a novel mechanism of action and minimal issues of toxicity ([@bib14]; [@bib25]; [@bib13]). Several plant-derived anticancer drugs are currently used in the treatment of cancer. They include vincristine, vinblastine, etoposide, teniposide, paclitaxel (taxol), docetaxel (taxotere), camptothecin, homoharringtonine and elliptinium ([@bib7]; [@bib32]; [@bib12]; [@bib45]). However, cancer cells are capable of developing resistance to the drugs used in chemotherapy. This fact, fact coupled with the increase in the cancer-related death rate has resulted in an ever-increasing demand for new anti-cancer entities ([@bib28]).

Medicinal orchids have been traditionally used in folk medicine for centuries as natural healing remedies with significant proven therapeutic effects ([@bib50]; [@bib34]). A large number of phytochemicals, including alkaloids, bibenzyl derivatives, flavonoids, and phenanthrenes, have been found in medicinal orchids ([@bib17]; [@bib35]). Their presence means that they can play a significant role in expressing different biological activities, including anti-microbial, anti-tumour, anti-inflammatory, anti-viral activities. Several orchid species have been studied, and a number of compounds which were isolated have been found to express cytotoxic activity ([@bib50]; [@bib28]; [@bib2]; [@bib39]). It is becoming increasingly clear that the beneficial effects of medicinal orchids are due to a complex interplay of the compounds present in the whole plant rather than to any single constituent operating on its own ([@bib9]; [@bib18]; [@bib22]). [@bib5] previously reported the antioxidant properties of the selected seven wild orchids of this study. Medicinal orchids exhibiting the profile of novel therapeutic and pharmaceutical compounds matching the demand for structurally diverse and unique novel small molecule entities, ultimately guiding lead discovery toward new drugs candidate ([@bib8]). The chances of obtaining active traditional medicine from orchids, which have been used to treat various diseases have been known for the past centuries. Thus, it is of great importance to document and screen them ([@bib29], [@bib30]; [@bib7]). A lot of compounds that have been isolated from orchids demonstrated significant anticancer activities. For example, moscatilin, denbinobin, erianin, dendrochrysanene, fimbriatone, and cirrohopetalanthrin have been isolated from various orchids ([@bib27]; [@bib19]; [@bib41]; [@bib58]; [@bib57]; [@bib6]; [@bib2]). The assessment of the cytotoxic potential of medicinal orchids serve as the baseline for the chemical identification of active molecules may be used as anticancer compounds which in turn could be chemically manipulated into effective anticancer drugs. These drugs could retard the growth of cancer cells and even cure cancer patients. Their creation would contribute positively to the economy of the country that produced them and to the world at large. Obtaining anticancer compounds from orchids should help reduce the unpleasant side effects associated with current cancer treatment methods as natural and semi-synthetic products are considered safer than synthetic drugs ([@bib54]). They could also be included in primary health care, as encouraged by the WHO ([@bib48]). Several natural products of plant origin are currently being subjected to clinical testing, but the search for new products remains of utmost importance as diseases, including cancer, are constantly developing resistance to existing drugs. This research highlight the screening of extracts of wild orchids for their cytotoxic effect toward the cancer cell lines which could help to promote the implementation of these therapeutically important medicinal orchids.

2. Materials and methods {#sec2}
========================

2.1. Collection of plant materials {#sec2.1}
----------------------------------

The different parts of seven wild orchids: pseudobulbs of *Eria graminifolia* (EGp) and *Otochilus albus* (OAp), stem of *Dendrobium transparens* (DTs), leaves of *Pholidota articulata* (PAl) as well as its pseudobulb (PAp), whole plant of *Gastrochilus distichus* (GDw) and *Papillionanthe uniflora* (PUw) and *Vanda cristata* (VCw) were collected from central Nepal between April and August 2016. Plants were identified by Asst. Prof. Dr. Mukti Ram Paudel and Prof. Dr. Bijaya Pant of Central Department of Botany, Tribhuvan University. The identities of these plants were confirmed concerning the literature, taxonomists and specimens in the Tribhuvan University Central Herbarium (TUCH), and voucher specimens were deposited at TUCH.

2.2. Preparation of extracts {#sec2.2}
----------------------------

The plant materials were air-dried in shade and then grounded to make powder. The powder was extracted in a sonicator using methanol in the ratio of 1:10 of weight/volume (w/v). The methanol is used as a solvent due to its low, therefore mild, boiling point and other favourable solvent properties applicable to secondary plant compounds. The solvent was evaporated under reduced pressure using a rotary evaporator and the crude extracts were kept at 4 °C for further biological in vitro test.

2.3. Cytotoxic effect of extracts {#sec2.3}
---------------------------------

The cytotoxic activity of the extracts was evaluated by using a standard MTT (3-\[4, 5-dimethylthiazole-2-yl\]-2, 5-diphenyl-tetrazolium bromide) colourimetric assay with a slight modification. Human cervical cancer (HeLa) and glioblastoma (U251) cells were cultured in EMEM medium supplemented with 10% FBS, 1% penicillin/streptomycin and 1% L-glutamine and incubated in 5% CO~2~ supplemented incubator at 37 °C ([@bib26]). The cells in 100μl medium were seeded in a 96-well plate (1 × 10^4^ to 2 × 10^4^ cells per well) and incubated in the above mentioned condition for 24 h. Thereafter, the cells were treated with different concentrations (50 μg/ml, 100 μg/ml, 200 μg/ml, and 400 μg/ml) of plant extracts for 48 h incubation. After that, the supernatant was replaced by 150 μl of medium with 50 μl of MTT in each well. Following the 4 h of incubation, purple formazan crystals of living cells were produced and they were dissolved by the addition of 100 μl of DMSO (0.1%). The absorbance was measured with a microplate reader at 595 nm. Commercially available cisplatin drug was used as a positive control. The percentage of the cytotoxic activity was calculated using the following formula$$\%\ \ cytotoxic\ \ activity = \frac{Abs1 - Abs2}{Abs1}\  \times 100$$Where Abs1 is the absorbance of cells with all components except plant extracts, Abs2 is the absorbance of the cells with all components including plant extracts.

2.4. Identification of compounds using GC-MS {#sec2.4}
--------------------------------------------

The bioactive compounds of the methanol extracts of *D. transparens* and *V. cristata* were identified by using GCMS-QP2010 Ultra (Shimadzu Europa GmbH, Germany). In GC-MS, an electron ionization system with ionization energy of 70 eV was used. The carrier gas was pure helium (99.99%) with a column-flow rate of 0.95 ml/min. The initial temperature was set at 100 °C and increased at a rate of 3 °C/min after a holding time of about 10 min. Finally, the temperature was raised to 300 °C at a rate of 10 °C/min. One microliter of 1% extract diluted in methanol was injected in a splitless mode. The relative quantity of compound present in the extract was expressed in a peak area produced in the chromatogram. Computer software was used to identify the compounds based on GC retention times and by matching the spectra with standard values.

2.5. Statistical analysis {#sec2.5}
-------------------------

The cytotoxic activity assay was carried out in triplicate. The values were presented as mean ± standard deviation (SD). The IC~50~ value of the extract was calculated using a second- or third-order polynomial regression equation.

3. Results and discussion {#sec3}
=========================

In the present study, eight methanol extracts of different concentrations (50, 100, 200, and 400 μg/ml) of seven wild orchids, none of whose cytotoxic activity has been previously reported on, were screened for their cytotoxic activities on two cancer cell lines (HeLa and U251) by using the MTT assay. The cytotoxic effect of these orchid extracts and commercial drug cisplatin against the cancer cell lines are presented in [Table 1](#tbl1){ref-type="table"}.Table 1Cytotoxic effect of extracts of selected wild orchids.Table 1SampleConcentration\
(μg/ml)HeLa cellsIC~50~ (μg/ml)U251 cellsIC~50~\
(μg/ml)% inhibition\
Mean ± SD% inhibition\
Mean ± SD*Gastrochilus distichus* (GDw)500No activity0No activity10000200004001.57 ± 0.100*Eria graminifolia* (EGp)5005219.850No activity100002001.57 ± 0.1004003.16 ± 0.050*Dendrobium transparens* (DTs)5020.65 ± 1.64382.1453.95 ± 0.3275.8410030.10 ± 0.7558.93 ± 0.1220038.41 ± 0.5764.95 ± 0.6340049.94 ± 0.7171.05 ± 0.64*Papilionanthe uniflora* (PUw)500781.8502585.88100002006.47 ± 0.032.50 ± 0.1140023.76 ± 0.086.58 ± 0.11*Otochilus albus* (OAp)5002345.190no activity10000200004007.55 ± 0.160*Pholidota articulata* (PAl)500673.0403170.551000020012.35 ± 0.07040027.20 ± 0.055.52 ± 0.11*Pholidota articulata* (PAp*)*50072303862.141000020010.37 ± 0.17040025.33 ± 0.054.49 ± 0.11*Vanda cristata* (VCw)5023.30 ± 2.29317.2341.24 ± 0.68163.6610033.41 ± 3.6947.94 ± 0.6320045.21 ± 1.7954.90 ± 0.7640054.56 ± 1.2961.86 ± 0.84Cisplatin drug\--25.00-25.00

The present study found that extracts of *D. transparens* stem (DTs) and *V. cristata* whole plant (VCw) were the most effective cytotoxicity toward both HeLa and U251 cancer cell lines with the lowest IC~50~ values as much as compared with the IC~50~ of cisplatin. The formazan crystals of living cells were formed after addition of MTT dye and no crystals were formed of cells those were killed by extracts. *P. uniflora* and *P. articulata* were not effective toward the cancer cell lines*.* Of the selected species, *G. distichus, E. graminifolia*, and *O. albus* were the least sensitive against these cancer cell lines.

Against HeLa cells, extracts of *E. graminifolia, G. distichus* and *O. albus* showed no evident cytotoxicity. *V. criststa, D. transparens*, *P. articulata* and *P. uniflora* exhibited significant cytotoxic activity of 49.56% 54.56%, 23.76% and 27.20%, respectively at the highest concentration (400 μg/ml). The 50% cell growth inhibition concentration (IC~50~) by the extracts of the selected orchids in the HeLa cell line was determined by using a linear regression equation of the percentage inhibition curve. The extracts of the whole plant of *V. cristata*, the stem of *D. transparens*, the leaf and pseudobulb of *P. articulata* and the whole plant of *P. uniflora* were effective cell growth inhibitors, with IC~50~ values of 317.23 μg/ml, 382.14 μg/ml, 673.04 μg/ml, 723 μg/ml and 781.85 μg/ml, respectively ([Table 1](#tbl1){ref-type="table"}).

In the case of U251 gliobastoma brain tumour cells, *D. transparens* and *V. cristata* were significantly effective in inhibiting growth, with percentage inhibition of 71.05% and 61.86%, respectively and IC~50~ of 75.84 μg/ml and 163.66 μg/ml, respectively, none of the other extracts demonstrated much cytotoxic activity against U251 cells ([Table 1](#tbl1){ref-type="table"}).

The bioactive compounds present in the extract obtained from *D. transparens* stem ([Table 2](#tbl2){ref-type="table"}) and *V. cristata* whole plant ([Table 3](#tbl3){ref-type="table"}) were detected and identified using GC-MS. The results of the GC-MS analysis of the other extracts are not shown here because those extracts showed either no or little inhibitory activity. The elution time of compounds with their base mass-to-charge ratio (m/z) and their contents by percentage were also determined.Table 2Bioactive compounds detected and identified from *Dendrobium transparens* stem extract.Table 2S.NCompound NameRT minContent %Base m/z11-hexadecene6.7350.1241.0521-pentadecene8.2170.1441.053Pentadecanal-8.5641.1768.054Phthalic acid butyl undecyl ester8.8671.08149511-octadecenoic acid methyl ester9.0371.7355.05614-methyl-pentadecanoic acid methyl ester9.15612.8674710-octadecenoic acid methyl ester10.31334.3255.05815-methyl-hexadecanoic acid methyl ester10.466.4374911,14-eicosadienoic acid methyl ester10.9182.0567.0510Hexanoic acid 9-decen-1-yl ester11.3810.984111Hexadecane11.6281.8257.05121,2-di-palmitin11.6863.1757.051310-oxo-octadecanoic acid methyl ester11.7492.3955.05142,6,10,15-tetramethyl-heptadecane12.2041.1157.051517-octadecynoic acid12.7444.6155.0516Hexadecane12.793.5457.117(*S*)-(+)-5-methyl-1-heptanol12.8331.2583.0518(*Z*)-13-docosenoic acid methyl ester12.8741.9555.05191,2-benzenedicarboxylic acid diisooctyl ester13.2252.08149206-ethyl-3-trimethylsilyloxydecane13.922.22131.121Hexadecane14.1571.6457.0522Cholesta-3,5-diene16.0292.2381.05231,1′-hexadecylidenebis-cyclopentane17.0683.53151.12410-undecenoic acid, propyl ester17.1571.5270.0525(*E,E,E*)-9-octadecenoic acid, 1,2,3-propanetriyl ester18.6282.0269.0526*beta*.-sitosterol20.3372.4943.05271-(2-decyldodecyl)-2,4-dimethyl-cyclopentane21.641.5655.05Table 3Bioactive compounds detected and identified from *Vanda cristata* whole plant extract.Table 3S.NCompound NameRT minContent (%)Base m/z1*alpha*-bisabolol7.6270.5943.05214-methyl-pentadecanoic acid methyl ester7.7571.2174.05310-Nonadecenoic acid methyl ester9.0373.5555.054Palmitic acid9.17223.5174510-octadecenoic acid methyl ester9.6790.4455.056Hexadecanoic acid9.8120.377479-methyl-octadecenoate10.34453.4355.05815-methyl-hexadecanoic acid methyl ester10.4684.86749Linolelaidoyl chloride10.6210.5467.05109,12-hexadecadienoic acid methyl ester10.9230.8167.05111,2--15,16-diepoxyhexadecane11.5920.655.05123,7-dimethyl-1,6-octadien-3-ol11.6370.5271.11311-tridecen-1-ol11.6942.7455.051410-oxo-octadecanoic acid methyl ester11.7511.0543.051515-methyl-hexadecanoic acid methyl ester11.8310.297416*E*-2-octadecadecen-1-ol12.0560.4755.05172-methyl-*Z,Z*-3,13-octadecadienol12.7482.9555.0518Erucic acid methyl ester12.8781.355.0519Docosanoic acid methyl ester13.0120.2874.0520Cyclohexane13.9220.49131.05

As major components were identified: palmitic acid (23.51%); 9- methyl-octadecanoate (53.43%); 10-octadecenoic acid, methyl ester (34.32%) and 14-methyl-pentadecanoic acid methyl ester (12.86%). As minor components by abundance were identified: 15-methyl-hexadecanoic acid methyl ester (6.43%), as well as below 5%, 1,2-di-palmitin; hexadecane; 1,1′-hexadecylidenebis-cyclopentane; 6-ethyl-3-trimethylsilyloxydecane; 9-octadecenoic acid; and 1,2,3-propanetriyl ester, which all of them were found to have various biological activities, including cytotoxic activity ([@bib1]; [@bib3]; [@bib23]; [@bib20]; [@bib33]). Besides these, *alpha*-bisabolol; 2-methyl-(*Z, Z*)-3,13-octadecadienol; hexadecanoic acid; docosenoic acid; 15-methyl-hexadecanoic acid methyl ester; 10-octadecenoic acid, and its methyl ester were also identified ([Table 2](#tbl2){ref-type="table"}). In *D. transparens*, a total of 27 compounds have been detected. Of them, the major components based on abundance were: 10-octadecenoic acid methyl ester (34.32%); 14-methyl-pentadecanoic acid methyl ester (12.86%). Minor components were: 15-methyl-hexadecanoic acid methyl ester (6.43%). Besides these, 1,2-*di*-palmitin; hexadecane; 1,1′-hexadecylidene- *bis*-cyclopentane and 6-ethyl-3-trimethylsilyloxydecane were also present ([Table 3](#tbl3){ref-type="table"}).

*Dendrobium nobile*, for example, showed cytotoxicity against human lung carcinoma, human ovary adenocarcinoma, and human promyelocytic leukemia cell lines ([@bib59]). *Dendrobium chrysanthum* inhibited the proliferation of HL-60 cells ([@bib24]), and *Bulbophyllum kwangtungense* showed antitumour activities against Hela and K562 human tumour cell lines ([@bib57]). *Bulbophyllum odoratissimum* was found to be cytotoxic against human cancer cell lines, such as human leukemia cell lines K562 and HL-60, human hepatoma BEL-7402, human lung adenocarcinoma A549 and human stomach cancer cell line SGC-7901 ([@bib6]) and *Dendrobium longicornu*, *D. amoenum*, *D. crepidatum* and *D. moniliforme* were found cytotoxic to HeLa and U251 cell lines ([@bib38], [@bib39]; [@bib40]; [@bib37]). Besides, compounds isolated from *Dendrobium* are found to have various antioxidant, anticancer, and neuroprotective activities ([@bib5]; [@bib31]). The majority of plant-based secondary metabolites consist of phenolic compounds, alkaloids, flavonoids and tannins ([@bib10]; [@bib56]; [@bib16]). These natural products possess diverse pharmacological properties, including cytotoxic and cancer chemopreventive effects. Flavonoids, triterpenoids and steroids, in particular, exert multiple biological effects due to their antioxidant properties and free radical-scavenging abilities ([@bib11]; [@bib16]). Studies have shown antioxidant and cytotoxic activity to be associated with a variety of classes of compounds, such as polyphenols, flavonoids, and catechins ([@bib55]). Also, almost all orchids inhibit endophytic fungi, surface saprophytes, latent pathogens and mycorrhizal fungi, at some stage of their lives ([@bib42]; [@bib44]; [@bib36]). Endophytes provide a broad variety of bioactive secondary metabolites with unique structures, including alkaloids, benzopyranones, chinones, flavonoids, phenolic acids, quinones, steroids, terpenoids, tetralones, and xanthones ([@bib53]; [@bib47]). The bioactive compounds in plants have a wide range of applications such as agrochemicals, antibiotics, immune-suppressants, and anti-diabetic, anti-inflammatory, anti-parasitics, antioxidants and anti-cancer agents ([@bib10]; [@bib15]; [@bib21]; [@bib46]; [@bib52]).

The mechanism behind the exhibited biological activity is unknown, however, the following mechanisms may be envisioned. Polyphenol compounds might inhibit cancer cells by xenobiotic-metabolizing enzymes that alter the metabolic activation of potential carcinogens, while some flavonoids may alter hormone production to prevent the development of cancer cells ([@bib6]; [@bib12]). Phenolics, on the other hand, may disrupt cellular division during the telophase stage of mitosis. Phenolics also reduce the amount of cellular protein, the mitotic index and colony formation during cell proliferation ([@bib24]; [@bib57]; [@bib40]). The more hydroxyl groups there are in a phenolic, the greater is its antioxidant activity. The presence of the 4-carbonyl group in the flavonoid molecule contributes to its anticancer activity ([@bib7]). Also, the presence of 2,3-double bond in a flavonoid molecule correlates with mitochondrial damage and cancer cell death ([@bib43]). Extracts of orchids have the potential to yield useful antioxidants and anticancer compounds which could lead to the production of valuable drugs and therefore merit more study to isolate such potentially useful drugs ([@bib8]).

4. Conclusion {#sec4}
=============

The methanol extracts of particular wild orchids of Nepal, in particular, *D. transparens* and *V. cristata,* showed significant cytotoxic activity against cervical cancer and brain tumour cell lines. Our results provide the basis for further investigation of these orchid species for the potential lead discovery of new chemical entities with therapeutic anti-cancer properties. Elucidating the mechanism of action by which these anti-cancer properties from the identified compounds are derived from, and their optimization towards a drug-like efficacy and safety profile is of crucial future importance.
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